Молекулярно-генетические и клинико-генотипические особенности муковисцидоза в российских популяциях
Диссертация
За последние двадцать лет развитие разнообразных техник молекулярных исследований привело к обнаружению более 1500 мутаций в гене CFTR, и к настоящему моменту для многих популяций и этнических групп определены специфичные панели мутаций. Работы по изучению спектра CFTR мутаций у российских больных MB велись разными группами исследователей нашей страны. Объединение этих данных позволяет сделать… Читать ещё >
Список литературы
- Амелина, E.JI. Муковисцидоз: определение продолжительности жизни / E.JI. Амелина, А. В. Черняк, А. Л. Черняев // Пульмонология. 2001. — № 3.- С. 61−64.
- Бермишева, М.А. Популяционно-генетическое исследование популяции удмуртов (анализ десяти полиморфных ДНК-локусов ядерного генома) / М. А. Бермишева, Н. В. Петрова, Р. А. Зинченко и др. // Генетика. 2007. — Т. 43,-№ 5.-С. 688−705.
- Ванин, А.Ф. Оксид азота регулятор клеточного метаболизма / А. Ф. Ванин // Соросовский образовательный журнал. — 2001. — № 11. — С. 7−12.
- Вознесенский, Н.А. Окись азота и легкие / Н. А. Вознесенский, А. Г. Чучалин, Н. С. Антонов // Пульмонология. 1998. — Т. 8, № 2. — С. 6−10.
- Воронкова, А.Ю. Клинические эффекты применения пульмозима / А. Ю. Воронкова // VII Национальный конгресс «Муковисцидоз 2005». — Сборник статей и тезисов: Воронеж, 2005. — С. 40−41.
- Воронкова, А.Ю. Дорназа альфа: клинические и лабораторные эффекты / А. Ю. Воронкова, Г. В. Шмарина, Л. Г. Дубовиц и др. // Пульмонология. -2006. Приложение по муковисцидозу. — С. 25−29.
- Гинтер Е.К. Медицинская генетика : Учебник / Е. К. Гинтер М.: Медицина, 2003. — 448 е.: ил. (Учеб. лит. для студентов мед. вузов). — ISBN 5−225−43 275.
- Голубцов, В.И. Редкие мутации гена CFTR у больных муковисцидозом в Краснодарском крае / В. И. Голубцов, Д. В. Рукавичкин, С. В. Морданов, С. И. Куцев // Медицинская генетика. 2007. — Т. 6. — № 9. — С. 15−19.
- Гуськова, А.А. Жизнь и смерть белка CFTR / А. А. Гуськова, М. Ю. Скоблов, А. В. Баранова // Медицинская генетика. 2007. — Т. 6. — № 2 (56). — С. 3−9.
- Жеребцова, A.JI. Изучение полиморфных маркеров ДНК в кандидатных генах болезни двигательного нейрона : дисс.. канд. мед. наук / Жеребцова А.Л.-М., 2006.-165 с.
- Животовский, Л. А. Популяционная биометрия / Л. А. Животовский // М.: Наука. 1991. — 271с. — ISBN 5−02−5 869−6.
- Иващенко, Т.Э. Муковисцидоз: молекулярно-генетический анализ гена, разработка новых подходов диагностики и генотерапии: автореф. дис.. д-ра биол. наук: 03.00.15 / Иващенко Татьяна Эдуардовна. М., 2000. — 46 с.
- Иващенко, Т.Э. Биохимические и молекулярно-генетические основы патогенеза муковисцидоза / Т. Э. Иващенко, B.C. Баранов // Спб.: Интермедика. 2002. — 256 с. — ISBN 5−89 720−043−2.
- Капранов, Н.И. Муковисцидоз (современные достижения и проблемы) ю Методоческие рекомендации / Н. И. Капранов, Л. А. Шабалова, Н. Ю. Каширская и др. // М.: Медпраьсгика. 2001. — С. 32−46.
- Капранов, Н.И. Муковисцидоз. Достижения и проблемы на современном этапе / Н. И. Капранов, Н. Ю. Каширская, Н. В. Петрова // Клиническая генетика. 2004. — № 9. — С. 398−412.
- Капранов, Н.И. Муковисцидоз современное состояние проблемы / Н. И. Капранов // Пульмонология. — 2006. — Приложение. — С. 5−11.
- Каширская, Н.Ю. Состояние желудочно-кишечного тракта, поджелудочной железы и гепатобилиарной системы у больных муковисцидозом : Автореф. дисс.. докт. мед. наук: 14.00.09 / Каширская Наталья Юрьевна М., 2001. -45 с.
- Корытина, Г. Ф. Анализ спектра мутаций и полиморфных локусов гена трансмембранного регуляторного белка муковисцидоза в Башкортостане / Г. Ф. Корытина, Т. В. Викторова, Г. В. Байкова, Э. К. Хуснутдинова // Генетика. 2002. — Т. 38, № 9. — С. 1270−1275.
- Корытина, Г. Ф. Полимофизм генов глутатион-Б-трансфераз Ml и PI у больных с муковисцидозом и хроничсескими заболеваниями дыхательной системы / Г. Ф. Корытина, Д. Г. Янбаева, Т. В. Викторова // Генетика. 20 046. -Т. 3, № 3. — С. 401−408.
- Кулинский, В.И. Обезвреживание ксенобиотиков / В. И. Кулинский // Соросовский образовательный журнал. 1999. — № 1. — С.8−12.
- Налбандян, Н.Г. Выявление спектра мутаций у пациентов с предполагаемым диагнозом муковисцидоз в Армянской популяцию / Н.Г.
- Налбандян, А.В. Аракелян // VIII Национальный конгресс «Муковисцидоз у детей и взрослых». Сборник статей и тезисов. — Ярославль, 2007. — С. 107.
- Наследственные болезни в популяциях человека / Под ред. Е. К. Гинтера. -М.: Медицина, 2002. 304 с.: ил. — ISBN 5−225−4 172−8.
- Насонов, Е.Л. Фактор некроза опухоли новая мишень для противовоспалительной терапии ревматоидного артрита / Е. Л. Насонов // Клиническая фармакология и терапия. — 2001. — № 1. — С. 64−70.
- Нурутдинова, О.С. Поиск мутаций в промоторной и 5'-дистальной областях гена муковисцидоза человека / О. С. Нурутдинова, Н. В. Петрова, А. В. Баранова и др. // Медицинская генетика. 2007. — Т. 6, № 3 (57). — С. 23−26.
- Пай, Г. В. Роль генетического полиморфизма эндотелиальной синтазы окиси азота (eNOS) в патогенезе некоторых профессиональных заболеваний / Г. В. Пай, Л. П. Кузьмина, Н. А. Лазарашвили и др. // Медицинская генетика. -2006.-Т. 5, № 7.-С. 47−50.
- Петрова, Н.В. Определение частоты мутации AF508 среди новорожденных города Москвы и оценка частоты муковисцидоза в Европейской части России / Н. В. Петрова, Е. К. Гинтер // Генетика. 1997. — Т. 33, № 9. — С. 1326−1328.
- Петрова, Н.В. Анализ частоты некоторых мутаций в гене CFTR в разных популяциях России / Н. В. Петрова, Е. Е. Тимковская, Р. А. Зинченко, Е. К. Гинтер // Медицинская генетика. 2006. — № 2. — С. 28−31.
- Потапова, О.Ю. Молекулярно-генетический анализ кистозного фиброза в России : автореф. дисс.. канд. биол. наук: 03.00.15 / Потапова Ольга Юрьевна / С.-Петербург: НИИЭМ РАМН. 1994. — 21 с.
- Руковичкин, Д.В. Клинико-генотипический полиморфизм муковисцмдоза среди населения Краснодарского края : дисс. канд.. мед. наук: 03.00.15 / Руковичкин Дмитрий Васильевич. Краснодар, 2007. — 27 с.
- Стекольников, А.А. Геногеографическая изменчивость Montivagum dihumerale и видообразование у клещей-краснотелок / А. А. Стекольников // Паразитология. 2006. — Т. 40, № 1. — С. 26−46.
- Тимковская, Е.Е. Анализ частот мутаций C282Y и H63D в гене HFE1 в некоторых популяциях европейской части России / Е. Е. Тимковская, Н. В. Петрова, Г. И. Ельчинова и др. // Медицинская генетика. -2006. Т. 5, № 5 (47). — С. 32−38.
- Хусаинова, Р.И. Скрининг Cys282Tyr и His63Asp в гене гемохроматоза у народов Волго-Уральского региона и Республики Саха (Якутия) / Р. И. Хусаинова, С. А. Федорова, Э. К. Хуснутдинова // Медицинская генетика. -2003.-Т. 2,№ 5.-С. 207−211.
- Хуснутдинова, Э.К. Популяционно-генетическая структура чуваешй (по данным о восьми ДНК-локусах ядерного генома) / Э. К. Хуснутдинова, Т. В. Викторова, B.JI. Ахметова и др. // Генетика. 2003. — Т. 39, № 11. — С. 15 501 563.
- Abdul Wahab, A. Heterogeneity of the cystic fibrosis phenotype in a large kindred family in Qatar with cystic fibrosis mutation (11234V) / A. Abdul Wahab, G. Al Thani, S.T. Dawod et al. // J. Trop. Paediatr. 2001. — V. 47. — P. 110−112.
- Abramowicz, M.J. Fetal bowel hyperechogenicity may indicate mild atypical cystic fibrosis: a case associated with a complex CFTR allele / M.J. Abramowicz, B. Dessars, C. Sevevs et al. // J. Ved. Genet. 2000. — V. 37. — E. 15.
- Ahmed, N. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas / N. Ahmed, M. Corey, G. Forstner et al. // Gut. 2003. — V. 52. — P. 1152−1164.
- Akar, N. Endothelial nitric oxide synthase intron 4, 27-bp repeat polymorphism in Turkish patients with deep vein thrombosis and cerebrovascular accidents / N. Akar, E. Akar, S. Cin et al. // Thrombosis Res. 1999. — V. 94. — P. 63−64.
- Alper, O.M. Detection of the novel CFTR mutations in Taiwanese cystic fibrosis patients / O.M. Alper, S.C. Shu, M.H. Lee et al. // J. Formos Med. Assoc. 2003. -V. 102, No. 5.-P. 287−291.
- Amaral, M.D. Processing of CFTR: Traversing the cellular maze- how much CFTR needs to go through to avoid cystic fibrosis? / M.D. Amaral // Pediatr. Pulmonol. 2005. — V. 39. — P. 479−491.
- Andersen, D.H. Cystic fibrosis of the pancreas / D.H. Andersen // J. Chron. Dis. -1958.-No. 7.-P. 58.
- Ashavaid, T.F. Molecular diagnosis of cystic fibrosis in Indian patients a preliminary report / T.F. Ashavaid, A.J. Dherai, A.A. Kondkar et al. // J. Assoc. Physicians India. -2003. -V. 51. — P. 345−348.
- Ashavaid, T.F. Application of multiplex ARMS and SSCP/HD analysis in molecular diagnosis of cystic fibrosis in Indian patients / T.F. Ashavaid, A.A. Kondkar, A.J. Dherai et al. // Mol. Diagn. 2005. — V. 9, No. 2. — P. 59−66.
- Assael, B.M. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years / B.M. Assael, C. Castellani, M. Barao Ocampo et al. // Am. J. Epidemiol. 2002. — V. 156. — P. 397−401.
- Banjar, H. Geographic distribution of cystic fibrosis transmembrane regulator gene mutations in Saudi Arabia / H. Banjar, M. Kambouris, B.F. Meyer et al. // Ann. Trap. Paediatr. 1999. — V. l 9. — P. 69−73.
- Bernig, T. Sequence analysis of the mannose-binding lectin (MBL2) gene reveals a high degree of heterozygosity with evidence of selection / T. Bernig, J.G. Taylor, C.B. Foster et al. // Genes Immun. 2004. — V. 5, No. 6. — P. 461−476.
- Bernig, T. An analysis variation across the MBL2 locus in Dutch Caucasians indicates that 3' haplotypes could modify circulating levels of mannose-binding lectin / T. Bernig, W. Breunis, N. Brouwer et al. // Hum.Genet. 2005. — V. 118 (3−4).-P. 404−415.
- Beutler, E. Mutation analysis in hereditary hemochromatosis / E. Beutler, T. Gelbart, C. West et al. // Blood Cells, Molecules, and Diseases. 1996. — V. 31. -P. 187−194.
- Blackman, S.M. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic finrosis / S.M. Blackman, R. Deering-Brose, R. McWilliams et al. // Gastroenterology. 2006. — V. 131, No. 4. — P. 1030−1039.
- Bobadilla, J.L. Cystic fibrosis: a worldwide analysis of CFTR mutations -correlation with incidence data and application to screening / J.L. Bobadilla, M. Macek Jr., J.P. Fine, P.M. Farrell // Hum. Mutat. 2002. — V. 19. — P. 575−606.
- Boldt, A.B. Diversity of the MBL2 gene in various Brasilian populations and the case of selection at the mannose-binding lectin locus / A.B. Boldt, L. Culpi, L.T. Tsuneto et al. // Hum. Immunol. 2006. — V. 67, No. 9. — P. 722−734.
- Bombieri, С. Frequency of large CFTR gene rearrangements in Italian CF patients / C. Bombieri, A. Bonizzato, C. Castellani et al. // Eur. J. Hum. Genet. -2005. V. 13, No. 5. — P. 687−689.
- Boyle, M.P. Strategies for identifying modifier genes in cystic fibrosis / M.P. Boyle // Proc. Am. Thorac. Soc. 2007. — V. 4. — P. 52−57.
- Brandt, N.J. Screening for carriers of cystic fibrosis. Result of a pilot study among pregnant women / N J. Brandt, M. Schwartz, F. Skovby // Ugeskr. Laeger. Article in Danish. 1994. — V. 156, (25). — P. 3751−3757.
- Brissot, P. Intestinal absorption of iron in HFE-1 hemochromatosis: local or systemic process? Review / P. Brissot, M.B. Troadec, O. Loreal // Journal of Hepatology. 2004. -V. 4. — P. 702−709.
- Brock, D.J. The incidence of cystic fibrosis in Scotland calculated from heterozygote frequencies / D.J. Brock, A. Gilfillan, S. Holloway // Clin. Genet. -1998.- V. 53, No. 1.- P. 47−49.
- Bronsfeld, I. Chloride conducdance and genetic background modulate the cystic fibrosis phenotype of AF508 homozygous twins and siblings / I. Bronsfeld, F. Mekus, J. Bijman et al. // J. Clin. Invest. -2001.-V. 108, No. 11.-P. 1705−1715.
- Brouillard, F. NF-kappa В mediates up-regulation of CFTR gene expression in Calu-3 cells by interleukin-lbeta / F. Brouillard, M. Bouthier, T. Leclerc et al. // J. Biol. Chem.- 2001. V. 276, No. 12. — P. 9486−9491.
- Brown, R. K. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress / R.K. Brown, H. Wyatt, J.F. Price, F.J. Kelly // Eur. Respir. J. -1996.-V. 9.-P. 334−339.
- Bucci, M. Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo / M. Bucci, F. Roviezzo, I. Posadas et al. // Proc. Natl. Acad. Sci. USA. 2005. — V. 102, No. 3. — P. 904−8.
- Buranawuti, К. Variants in mannose-binding lectin and tumor necrosis factor {alpha} affect survival in cystic fibrosis / K. Buranawuti, M.P. Boyle, S. Cheng et al. // J. Med.Genet. 2007. — V. 44, No. 3. — P. 209−214.
- Burke, W. Variable severity of pulmonary disease in adults with identical cystic fibrosis mutations / W. Burke, M.L. Aitken, S.H. Chen et al. // Chest. 1992. — V. 102.-P. 506−509.
- Burt, M.J. The significance of haemochromatosis gene mutations in the general population: implications for screening / M.J. Burt, P.M. George, J.D. Upton et al. // Gut. 1998. — V. 43, No. 6. — P. 830−836.
- Cabello, G.M. The 3120+1G—>A splicing mutation in CFTR in common in Brazilian cystic fibrosis patients / G.M. Cabello, E.H.Jr.J.L. Cabello, O. Fernande, A. Harris // Hum. Biol. 2001. — V. 73, No. 3. — P. 403−409.
- Cantlay, A.M. Heterogeneous expression and polymorphic genotype of glutathione S-transferases in human lung / A.M. Cantlay, C.A. Smith, W.A. Wallace, et al. // Thorax. 1994. — V. 49, No. 10. — P. 1010−1014.
- Cardoso, C.S. Co-selection of the H63D mutation and the HLA-A29 allele: a new paradigm of linkage disequilibrium? / C.S. Cardoso, H. Alves, M. Mascarenhas et al. // Immunogenetics. 2002. — V. 53, No. 12. — P. 1002−8.
- Castellani, C. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers / C. Castellani, L. Picci, M. Scarpa et al. // Am. J. Med. Genet. A.-2005.-V. 135, No. 2.-P. 142−144.
- Castellani, C. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice / C. Castellani, H. Cuppens, M. Macek Jr. et al. // J. Cyst. Fibr. 2008. — V. 8. — P. 179−196.
- Chen, H.J. Cystic fibrosis with homozygous R553X mutation in a Taiwanese child / H.J. Chen, S.P. Lin, H.C. Lee et al. // J. Hum. Genet. 2005. — V.50, No. 12.-P. 674−678.
- Chevalier-Porst, F. Identification and characterization of three large deletions and a deletion/polymorphism in the CFTR gene / F. Chevalier-Porst, G. Souche, D. Bozon // Hum. Genet. 2005. — V. 25. — P. 504.
- Chiba-Falek, O. The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10kbC>T mutation / O. Chiba-Falek, E. Kerem, T. Shoshani et al. // Genomics. 1998. -V. 53. — P. 276−283.
- Chiba-Falek, O. Variable levels of normal RNA in different organs carrying the slicing mutation 3849+10kbC>T / O. Chiba-Falek, R.B. Parad, E. Kerm, B. Kerem //Am. J. Respir. Crit. Care Med. 1999. -V. 159. — P. 1998−2002.
- Chillon, M. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens / M. Chillon, T. Casals, B. Mercier, et al. // N. Engl. J. Med. 1995. — V. 332. — P. 1475−1480.
- Chmiel, J.F. State of art: why do the lungs of patients with cystic fibrosis become infected and why can’t they clear the infection? / J.F. Chmiel, P.B. Davis // Respir. Res.-2003.-V. 4.-P. 8.
- Chou, J.L. Characterization of the promoter region of the cystic fibrosis transmembrane conductance regulator gene / J.L. Chou, R. Rozmahel, L.C. Tsui // J. Biol. Chem. 1991. — V. 266, No. 36. — P. 24 471−24 476.
- Chu, C.S. Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator mRNA transcripts in normal bronchialepithelium / C.S. Chu, B.S. Trapnell, JJJr. Murtagh et al. // EMBO J. 1991. -V. 10.-P. 1355−1363.
- Chu, C.S. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA / C.S. Chu, B.S. Trapnell,
- Curristin et al. // Nature Genet. 1993. — V. 3. — P. 151 -156.
- Clancy, J.P. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis / J.P. Clancy, Z. Bebok, F. Ruiz et al. // Am. J. Respir. Crit. Care. 2001. -V. 163. — P. 1683−1692.
- Claustres, M. CFTR haplotypic variability for normal and mutants genes in cystic fibrosis families from southern France / M. Claustres, M. Desgeorges, Ph. Moine et al. //Hum. Genet. 1996. -V. 98. — P. 336−344.
- Clausters, M. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France / M. Clausters, C. Guittard, D. Bozon et al. // Hum. Mutat. 2000. — V. 16. — P. 143−156.
- Cohen, J.C. Pathophysiologic consequences following inhibition of a CFTR-dependent development cascade in the lung / J.C. Cohen, J.E. Larson // BMC Developmental Biology. 2005. — V. 5, No.2. — doi:10.1186/1471−213X-5−2.
- CoIIazo, T. Frequency of delta-F508 mutation and XV2C/KM19 haplotypes in Cuban cystic fibrosis families / T. Collazo, C. Magarino, R. Chavez et al. // Hum. Hered. 1995. — V. 45. — P. 55−57.
- Connelly, L. Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression / L. Connelly, A.T.
- Jacobs, M. Palacios-Callender et al. // J. Biol. Chem. 2003. — V. 278, No. 29. — P. 26 480−26 487.
- Correlation between genotype and phenotype in patients with cystic fibrosis / Cystic fibrosis genotype-phenotype consortium (CFGPC) // N. Engl. J. Med. -1993.-Vol. 329.-P. 1308.
- Crossley, J. R. Dried-blood spot screening for cystic fibrosis in the newborn / J. R. Crossley, R. B. Elliott, P. A. Smith // Lancet. 1979. — i: 472.
- Cuthbert, A.W. The genetic advantage hypothesis in cystic fibrosis heterozygotes: a murine study / A.W. Cuthbert, J. Halstead, R. Ratcliff et al. // J. Physiol. 1995. — V.482, Pt2. — P. 449−454.
- Dankert-Roelse, J.E. Long term prognosis of patients with cystic fibrosis in relation to early detection by neonatal screening and treatment in a cystic fibrosis centre / J.E. Dankert-Roelse, G.J. te Meerman // Thorax. 1995. — V. 50. — P. 712−8.
- Dankert-Roelse, J.E. Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe / J.E. Dankert-Roelse, M.E. Merelle // J. Pediatr. 2005. — V. 147 (3 Suppl.). — S15−20.
- Davies, M.H. GSTM1 null polymorphism at the glutathione S-transferase Ml locus: phenotype and genotype studies in patients with primary biliary cirrhosis /
- M.H. Davies, Е. Elias, S. Acharya et al. // Gut. 1993. — V. 34, No. 4. — P. 549 553.
- Davies, J. Differential binding of mannose-binding lectin to respiratory pathogens in cystic fibrosis / J. Davies, O. Neth, E. Alton et al. // Lancet. 2000. -V. 355 (9218).-P. 1885−1886.
- Davies, J. Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles / J. Davies, M.W. Turner, N. Klein et al. // Eur. Respir. J. 2004. -V. 24.-P. 798−804.
- Davis, P.B. Cystic fibrosis: state of the art / P.B. Davis, M. Drumm, W. Konstan // Am. J. Respir. Crit. Care Med. 1996. — V. 154. — P. 1229−1256.
- Dean, M. Approaches to localizing disease genes as applied cystic fibrosis / M. Dean, M.L. Drumm, C. Stewart et al. // Nuc. Ac. Res. 1990. — V. 18. — No. 2. -P. 345−350.
- Demko, C.A. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence / C.A. Demko, R.C. Stern, C.F. Doershuk // Pediatr. Pulmonol. -1998. V. 25, No. 5. — P. 304−308.
- Devaney, J. HFE Alleles in an Irish Cystic Fibrosis Population / J. Devaney, M. Maher, T. Smith et al. // Genetic Testing. 2003. — V. 7. — No. 2. — P. 155−158.
- Dodge, J. Cystic fibrosis mortality and survival in the United Kingdom, 1947 to 2003 / J. Dodge, P.A. Lewis, M. Stanton et al. // Eur. Respir. J. 2007. — V. 29, No. 3.-P. 522−526.
- Dorfman, R. Complex two-gene modulation of lung disease severity in children with cystic fibrosis / R. Dorfan, A. Sandford, C. Taylor et al. // J. Clin. Invest. -2008.-V. 118, No. 3.-P. 1040−1048.
- Doring, G. Early Intervention and Prevention of Lung Disease in Cystic Fibrosis / G. Doring, N. Hoiby // Cyst. Fibros. 2004. — V. 3, No. 2. — P. 67−91.
- Dork, T. Cystic fibrosis with three mutations in the cystic fibrosis transmembrane conductance regulator gene / T. Dork, U. Wulbrand, T. Richter et al. // Hum. Genet. 1991. — V. 87. — P. 441−446.
- Dork, T. Characterization of a novel 21-kb deletion, CFTRdele2,3(21kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and
- East Europe / Т. Dork, M. Maeek Jr., F. Mekus et al. // Hum. Genet. 2000. — V. 106.-P. 259−268.
- Dotsch, J. Airway nitric oxide in asthmatic children and patients with cystic fibrosis / J. Dotsch, S. Demirakca, H.G. Terbrack et al. // Eur. Respir. J. 1996. -V. 9, No. 12.-P. 2537−40.
- Doull, I.J.M. Cystic fibrosis-related deaths in infancy and the effect of newborn screening / I.J.M. Doull, H.C. Ryley, P. Weller et al. // Pediatr. Pulmonol. 2001. -V. 31.-P. 363−366.
- Drumm, M.L. Genetic modifiers of lung disease in cystic fibrosis / M.L. Drumm, M.W. Konstan, M.D. Schluchter et al. // N. Engl. J. Med. 2005. — V.6, 353(14).-P. 1443−53.
- Dudding, T. Neonatal screening for cystic fibrosis / T. Dudding, B. Wilcken, B. Burgess, G. Turner // Lancet. 2000. — V. 356. — P. 1930.
- Enattah, N.S. Evidence of still-ongoing convergence evolution of the lactase persistence T-13 910 alleles in humans / N.S. Enattah, A. Trudeau, V. Pimenoff et al. // Am. J. Hum. Genet. 2007. — V. 81, No. 3. — P. 615−626.
- Engracia, V. Expression of Class m Glutathione-S-Transferase in human liver and its association with hepatopathies / V. Engracia, M.M.B.S. Leite, R.C. Pagotto et al. //Am. J. of Med. Gen. -2003. V. 123 A. — P. 257−260.
- Epaud, R. Mild cystic fibrosis revealed by persistent hyponatremia during the Freeh heat wave, associated with the S1455X C-terminus CFTR mutation / R. Epaud, E. Girodon, H. Corvol et al. // Clin. Genet. 2005. — V. 68, No. 6. — P. 552−553.
- Eskandarani, H.A. Cystic fibrosis transmembrane conductance regulator gene mutations in Bahrain / H.A. Eskandarani // J. Trop. Haediatr. 2002. — V. 48. — P. 348−350.
- Estivill, X. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium / X. Estivill, C. Bancells, C. Ramos // Hum. Mutat. 1997. — V.10, No. 2.-P. 135−154.
- Farber S. The relation of pancreatic achylato meconium ileus / S. Farber // J. Pediat. 1946. — No. 24. — P. 387−392.
- Farinha, C.M. Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin / C.M. Farinha, M. D. Amaral // Mol. Cell. Biol.-2005.- V.25.-No. 12.-P. 5242−5252.
- Farrell, P.M. Sweat chloride concentrations in infants homozygous of heterozygous for F508del cystic fibrosis / P.M. Farrell, R.E. Koscik // Pediatrics. -1996.-V. 97.-P. 524−528.
- Farrell, P.M. Prenatal screening for cystic fibrosis: Where are we now? / P.M. Farrell, N. Fost //J. Pediatr. -2002. V. 141.-P. 758−63.
- Farrell, P.M. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! / P.M. Farrell, FL. Lai, Z. Li et al. // J. Pediatr. 2005. — V. 147 (3 Suppl.). — S. 30−36.
- Feldman, G.L. Prenatal diagnosis of cystic fibrosis by DNA amplification, detection of KM-19 polymorphism / G.L. Feldman, R. Williamson, A.L.'Beaudet, W.E. O’Brien // Lancet. 1988. — July 9. — V. 2 (8602) — P. 102.
- Ferrari, M. Genotype phenotype correlation in cystic fibrosis patients / M. Ferrari, L. Cremonesi // Ann. Biol. Clin. (Paris). -1996. — V. 54, No. 6. — P. 235 241.
- Field, M. Toxigenic diarrheas, congenital diarrheas, and cystic fibrosis: disorders of intestinal ion transport / M. Field, C.E. Semrad // Annu. Rev. Phisiol. 1993. — V. 55.-P. 631−655.
- Flamant, C. Glutathione-S-transferase Ml, M3, PI and T1 polymorphisms and severity of lung disease in children with cystic fibrosis / C. Flamant, A. Henrion-Caude, P. Y. Boelle et al. // Pharmacogenetics. 2004. — V. 14. — P. 295−301.
- Fodinger, M. Low clinical penetrance of homozygosity for HFE C282Y: implications for genetic testing? / M. Fodinger, G. Sunder-Plassmann // Eur. J. Clin. Invest. 2003. -V. 33, No. 9. — P. 737−739.
- Freedman, S.D. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr (-/-) mice / S.D. Freedman, M.N. Katz, E.M. Parker et al. // Proc. Natl. Acad. Sci. USA 1999. — V. 96, No. 24. — P. 1 399 514 000.
- Friedman, K.J. Complex multigenic inheritance influences the development of severe liver disease in CF / K.J. Friedman, S.C. Ling, M. Macek Jr. et al. // In: Proceedings of the 15th North American Cystic Fibrosis Conference. Orlando, Fl.- 2001.
- Frossard, P.M. Identification of cystic fibrosis mutations in Oman / P.M. Frossard, K.P. Dawson, S.J. Das et al. // Clin. Genet. 2000. — V. 57. — P. 235 236.
- Gabold, M. Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study / M. Gabold, M. Guilloud-Bataille, J. Feingold et al. // В. M. J. 1999. -V. 319. — P. 1166−1167.
- Gabold, M. The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis / M. Gabold, D. Hubert, M. Guilloud-Bataille et al. // J. Med. Genet. 2001. — V. 38. — P. 310−311.
- Gabriel, S.E. Cystic fibrosis heterozygote resistance to holera toxin in the cystic fibrosis mouse model / S.E. Gabriel, K.N. Brigman, B.H. Koller et al. // Science. -1994.-V. 266.-P. 107−109.
- Gaitskhoki, V.S. Linkage disequilibrium between cystic fibrosis mutations and polymorphic 4-bp repeat within CFTR gene / V.S. Gaitskhoki, O.V. Voronina, O.Y. Potapova et al. // Biochemical Medicine and Metabolic Biology. 1993. — V. 50.-P. 186−189.
- Gan, K.H. A cystic fibrosis mutation associated with mild lung disease / K.H. Gan, HJ. Veeze, M.W. Van Den Ouweland et al. // N. Engl. J. Med. 1995. — V. 333.-P. 95−99.
- Garred, P. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis / P. Garred, T. Pressler, H.
- Madsen et al. // J. Clin. Invest. 1999. — V. 104, No. 4. — P. 431−437.
- Garred, P. Mannose-binding lectin deficiency-revisited / P. Garred, F. Larsen, H.O. Madsen, C. Koch // Mol. Immunol. 2003. — V. 40. — P. 73−84.
- Georges des, M. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities / M. des Georges, A. Megarbane, C. Guittard et al. // Hum. Genet. 1997. — V. 100, No. 2. — P. 279−283.
- Georges des, M. High heterogeneity of CFTR mutations and unexpected low incidence of cystic fibrosis in the Mediterranean France / M. des Georges, C. Guittard, J. Altieri et al. // J. Cyst. Fibros. 2004. — V. 3, No. 4. — P. 265−272.
- Ghobadloo, S.M. GSTP1, GSTM1, and GSTT1 genetic polymorphisms in patients with cryptogenic liver cirrhosis / S.M. Ghobadloo, B. Yaghmaei, V. Bakayev et al. // J. Gastrointest. Surg. 2004. -V. 8, No. 4. — P. 423−427.
- Ghobadloo, S.M. Polymorphisms of glutathione S-transferase Ml, Tl, and PI in patients with HBV-related liver cirrhosis, chronic hepatitis, and normal carriers / S.M.Ghobadloo, B. Yaghmaei, A. Allameh et al. // Clin. Biochem. 2006. — V.1.P. 46−49.
- Girardet, A. Negative genetic neonatal screening for cystic fibrosis caused by compound heterozygosity for two large CFTR rearrangements / A. Girardet, C. Guittard, J.-P. Altieri et al. // Clin. Genet. 2007. — V. 72. — P. 374−377.
- Glanzmann, R. Disporia entero-broncho-pancreatita, familaris / R. Glanzmann // Ann. Paediat. (Basel). 1946. -N. 169. — P. 289−337.
- Goh, B.J. Nitric oxide synthase and heme oxygenase expressions in human liver cirrhosis / B.J. Goh, B.T. Tan, W.M. Hon et al. // World J. Gastroenterol. 2006. -V. 12, No. 4.-P. 588−594.
- Goldman, A. The molecular basis of cystic fibrosis in South Africa / A. Goldman, R. Labrum, M. Claustres et al. // Clin. Genet. 2001. — V. 59. — P. 3741.
- Gong, M.N. -308GA and TNFB polymorphisms in acute respiratory distress syndrome / M.N. Gong, W. Zhou, P.L. Williams et al. // Eur. Respir. J. 2005. -V.26.-P. 382−389.
- Gracia de, J. Genotype-phenotype correlation for pulmonary function in cystic fibrosis / J. de Gracia, F. Mata, A. Alvarez et al. // Thorax 2005. — V.60. — P. 558−563.
- Grasemann, H. Endothelial nitric oxide synthase variants in cystic fibrosis lung disease / H. Grasemann, K.S. Gravesande, R. Buscher et al. // Am. J. Respir. Crit. Care Med. 2003. — V. 167. — P. 390−394.
- Green, M.R. Early and late outcome of cystic fibrosis screening / M.R. Green, L.T. Weaver // Journal of the Royal Society of Medicine. 1994. — Suppl. — No. 21.-V. 87.-P. 5−10.
- Gregg, R. Cystic fibrosis carrier frequency determined by newborn screening and by dF508 analysis of the general population / R. Gregg, B. Wilfond, A. Laxova et al. //Pediatric. Pulm. 1991. — V. 238, No. 55. — P. 189−202.
- Gregg, R.G. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods / R.G. Gregg, A. Simantel, P.M. Farrell et al. // Pediatrics. 1997. — V. 99, No. 6. — P. 819−824.
- Grubb, B.R. Intestinal physiology and pathology in gene-targeted mouse-models of cystic fibrosis / B.R. Grubb, S.L. Gabriel // Am. J. Physiol. 1997. — V.273. G258-G266.
- Hamosh, A. Comparison of the clinical manifestation of cystic fibrosis black and white patients / A. Hamosh, S.C. Fitz-Simmons, M. Macek, Jr. et al. // J. Pediatr.- 1998.-V. 132.-P. 255−259.
- Hanson, E. HFE gene and hereditary hemochromatosis: a Huge review. Human Genome Epidemiology / E. Hanson, G. Imperatore, W. Burke // Am. J. Epidemiol. -2001.-V. 154, No. 3. P. 193−206.
- Hardin, D.S. Mechanisms of insulin resistance in cystic fibrosis / D.S. Hardin, A. Leblanc, G. Marshall, D.K. Seilheimer // Am. J. Physiol. Endocrinol. Metab. -2001.-V. 281, No. 5.-E. 1022−1028.
- Hendry, J. Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa / J. Hendry, J.S. Elborn, L. Nixon, et al. // Eur. respir. J. 1999. — V. 14. — P. 435−438.
- Henrion-Caude, A. Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase PI polymorphism / A. Henrion-Caude, C. Flamant, M. Roussey et al. // Hepatology. 2002. — V. 36, No. 4. — P. 913−917.
- Highsmith, W.E. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations / W.E. Highsmith, L.H. Burch, Z. Zhou et al. //N. Engl. J. Med. 1994. — V. 331. — P. 974−980.
- Hodson, M.E. Cystic Fibrosis / M.E. Hodson, M.G. Duncan // Arnold, a •- member of the Hodder Headline Group. London, UK. — 2000. — 477p.
- Hollox, E.J. Lactase haplotype diversity in the Old World / E.J. Hollox, M. Poulter, M. Zvarik et al. // Am. J. Hum. Genet. 2001. — V. 68. — P. 160−172.
- Huang, S.L. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis / S.L. Huang, C.H. Su, S.C. Chang // Am. J. Respir. Crit. Care Med. -1997.-V.156.-P. 1436−1439.
- Hull, J. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis / J. Hull, A. H. Thomson // Thorax. 1998. — V. 53. — P. 10 181 021.
- Hytonen, M. Cystic fibrosis gene mutations deltaF508 and 394delTT in patients with chronic sinusitis in Finland / M. Hytonen, M. Patjas, S.I. Vento et al. // Acta Otolaryngol.-2001.-V. 121, No. 8, — P. 945−947.
- Imaizumi, Y. Incidence and mortality rates of cystic fibrosis in Japan // Y. Imaizumi // Am. J. Med. Genet. 1995. — V. 28- 58 (2). — P. 161−168.
- Jenkins, R.G. Pulmonary gene therapy. Realistic hope for the future, or false dawn in the promised land? / R.G. Jenkins, R.J. McAnulty, S.L. Hart, G.J. Laurent // Monaldi. Arch. Chest. Dis. 2003. — V. 59, No. 1. — P. 17−24.
- Jentsch, T.J. Chloride channel diseases resulting from impaired transepithelial transport or vesicular function / T.J. Jentsch, T. Maritzen, A.A. Zdebik // J. Clin. Invest. 2005. — V. 115. — P. 2039−2046.
- Jorde, L.B. A test of the heterozygote-advantage hypothesis in cystic fibrosis carriers / L.B. Jorde, G.M. Lathrop // Am. J. Hum. Genet. 1988. — V. 42, No. 6. -P. 808−815.
- Kabra, S.K. Clinical profile and frequency of delta F508 mutation in Indian children with cystic fibrosis / S.K. Kabra, M. Kabra, R. Lodha et al. // Indian Pediatr. 2003. — V. 40. — P. 612−619.
- Kallianpur, A.R. Increased prevalence of the HFE C282Y hemochromatosis allele in women with breast cancer / A.R. Kallianpur, L.D. Hall, M. Yadav et al. // Cancer Epidemiol. Biomarkers Prev. 2004. — V. 13, No. 2. — P. 205−212.
- Kalman, Y.M. Difference in frequencies of the cystic fibrosis alleles, delta F508 and W1282X, between carriers and patients / Y.M. Kalman, E. Kerem, A. Darvasi et al. // Eur. J. Hum. Genet. 1994. — V. 2, No. 2. — P. 77−82.
- Kaplan, N.L. Age of the AF508 cystic fibrosis mutation / N. L. Kaplan, P. O. Lewis, B. S. Weir//Nat. Genet. 1994. -V. 8. — P. 216−218.
- Kapoor, V. Carrier frequency of F508del mutation of cystic fibrosis in Indian population / V. Kapoor, S.S. Shastri, M. Kabra et al. // J. Cyst. Fibros. 2006. -V. 5, No. l.-P. 46−49.
- Kerem, B.S. Identification of the cystic fibrosis gene: Genetic analysis / B.S. Kerem, J.M. Rommens, J.A. Buchanan et al. // Science. 1989. — V. 245. — P. 1073−1080.
- Kerem, B.S. The molecular basis for disease variability in cystic fibrosis / B.S. Kerem, E. Kerem // Eur. J. Hum. Genet. 1996. — V. 4. — P. 65−73.
- Kerem, E. The relation between genotype and phenotype in cystic fibrosis -analysis of the most common mutation (delta F508) / E. Kerem, M. Corey, B.S. Kerem et al. //N. Engl. J. Med. 1990. — V. 323. — P. 1517−1522.
- Kerem, E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough? / E. Kerem // Curr. Opin. Pulm. Med. 2004. — V. 10. — P. 547−552.
- Kerem, E. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation specific therapy / E. Kerem // Pediatr. Pulmonol. 2005. — V. 40, No. 3.-P. 183−196.
- Kerem, E. Mutation specific therapy in CF / E. Kerem // Paediatr. Respir. Rev. 2006. — V. 7. — Suppl.l. — S. 166−169.
- Kiesewetter, S. A mutation in CFTR produces different phenotypes depending on chromosomal background / S. Kiesewetter, M. Macek Jr., C. Davis et al. // Nat. Genet. 1993. — V. 5. — P. 274−278.
- Kim, Y.J. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis В virus infection / Y.J. Kim, H.-S. Lee, J.-H. Yoon et al. // Hum. Molec. Genet. 2003. — V. 12. — P. 2541−2546.
- Kinnunen, S. Spectrum of mutations in CFTR in Finland: 18 years follow-up study and identification of two novel mutations / S. Kinnunen, S. Bonache, T. Casals et al. // J. Cyst. Fibr. 2005. — V. 4, No. 4. — P. 233−237.
- Koch, C. Early Infection and Progression of Cystic Fibrosis Lung Disease / C. Koch // Pediatric. Pulmonology. 2002. — V. 34. — P. 232−236.
- Kogan, I. CFTR directly mediates nucleotide-regulated glutathione flux / I. Kogan, M. Ramjeesingh, C. Li et al. // The EMBO J. 2003. — V. 22, No. 9. — P. 1981−1989.
- Koh, J. Characterization of the cystic fibrosis transmembrane conductance regulator promoter region / J. Koh, T.J. Sferra, F.S. Collins // J. Biol. Chem. -1993. V. 268, No. 21. — P. 15 912−15 921.
- Krawczak, M. Allelic association of the cystic fibrosis locus and DNA markers, XV-2c and KM19, in 55 German families / M. Krawczak, D.S. Konecki, J. Schmidtke et al.//- 1988.-V. 80, No. l.-P. 78−80.
- Kristidis, P. Genetic determination of exocrine pancreatic function in cystic fibrosis / P. Kristidis, D. Bozon, M. Corey et al.// Am. J. Hum. Genet. 1992. — V. 50.-P. 1178−1184.
- Kusemko, J. A. Screening, early neonatal diagnosis and prenatal diagnosis / J.A. Kusemko // Journal of the Royal Society of Medicine. 1986. — Suppl. -No. 12.-V. 79.-P. 2−5.
- Lao, O. Spatial patterns of cystic fibrosis mutations spectra in European populations / O. Lao, A.M. Andres, E. Mateu et al. // Eur. J. Hum. Genet. 2003. -V. 11.-P. 385−394.
- Larriba, S. Testicular CFTR splice variants in patients with congenital absence of vas deferens / S. Larriba, L. Bassas, J. Gimenez et al. // Hum. Mol. Genet. -1998.-V. 7.-P. 1739−1743.
- Lee, J.H. A haplotype-based molecular analysis of CFTR mutations associated with respiratory and pancreatic diseases / J.H. Lee, J.H. Choi, W. Namkung et al. //Hum. Mol. Genet -2003. -V. 12. P. 2321−2332.
- Lee, S.G. Analysis of mannose-lectin 2 (MBL2) genotype and the serum protein levels in the Korean population / S.G. Lee, J.S. Yum, H.M. Moon et al. // Mol. Immunol. 2005. — V. 42, No. 8. — P. 969−977.
- Lee, Y.H. Meta-analysis of TNF-alpha promoter -308A/G polymorphism and SLE susceptibility / Y.H. Lee, J.. Harley, S. K. Nath // Europ. J. Hum. Genet. -2006.- V. 14.-P. 364−371.
- Li, C. Lysophosphatic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions / C. Li, K.S. Dandridge, A. Di et al. // J. Exp. Med. 2005. — V. 202, No. 7. — P. 975−986.
- Loubieres, Y. Association between genetically determined pancreatic status and lung disease in adult cystic fibrosis patients / Y. Loubieres, D. Grenet, B. Simon-Bouyet al.//CHEST. 2002. — V. 121, No. l.-P. 73−80.
- Lucotte, G. Geographic and ethnic distribution of the more frequent cystic fibrosis mutations in Europe show that a founder effect is apparent for several mutant alleles / G. Lucotte, S. Hazout // Hum. Biol. 1995. — V. 67. — No. 4. — P. 561−576.
- Ma, Т. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion / T. Ma, J.R. Thiagarajah, H. Yang et al.//J. Clin. Invest. 2002. — V. 110, No. 11.-P. 1651−1658.
- Madsen, H.O. Different molecular events result in low protein levels of mannan-binding lectin on populations from Southeast Africa and South America / H.O. Madsen, M.L. Satz, B. Hogh et al. // J. Immunol. 1998. — V. 161. — P. 3169−3175.
- Magnani, C. Informativity of intragenic microsatellites for carrier detection and prenatal diagnosis of cystic fibrosis in the Italian population / Magnani C, Cremonesi L., Belloni E. et al.// Clin.Genet. 1994. — V.45. -N.3. — P.135−139.
- Mahadeva, R. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study / R. Mahadeva, K. Webb, R.C. Westerbeek et al. // B.M.J. 1998. — V. 316. — P. 1771−1775.
- Мак, V. Higher proportion of intact exon 9 mRNA in nasal epithelium* compared with vas deferens / V. Мак, K.A. Jarvi, J. Zielenski et al. // Hum. Mol. Genet. 1997. — V. 6. — P. 2099−2107.
- Martin, A.M. Population frequencies of single nucleotide polymorphisms (SNPs) in immuno-modulatory genes / A.M. Martin, G. Athanasiadis, J.D. Greshok et al. // Hum. Hered. 2003. — V. 55, No. 4. — P. 171−178.
- Martin, P.M. Expression and polarized localization of the hemochromatosis gene product HFE in retinal pigment epithelium / P.M. Martin, J.P. Gnana-Prakasam, P. Roon et al. // Invest. Ophthalmol. Vis. Sci. 2006. — V. 47, No. 10. -P. 4238−4244.
- Maselli, J.H. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening / J.H. Maselli, M.K. Sontag, J.M. Norris et al. // Pediatr. Pulmonol. 2003, — V. 35. — P. 257−262.
- Masotti, С. A functional SNP in the promoter region of TCOF1 is associated with reduced gene expression and YY1 DNA-protein interaction / C. Masotti, L.M. Armelin-Correa, A. Splendore et al. // Gene. 2005. — V. 359. — P. 44−52.
- Massie, R.J. Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989−1998). / R.J. Massie, M. Olsen, J. Glazner et al. // Med. J. Aust. 2000. — V. 172. — P. 584−587.
- Mastella, G. Neonatal screening for cystic fibrosis: long-term clinical balance / G. Mastella, L. Zanolla, C. Castellani et al. // Pancreatology. 2001. — V. 1, No. 5. -P. 531−537.
- Mateu, E. Allele frequencies is a worldwild survey of a CA repeat in the first intron of the CFTR gene / E. Mateu, F. Calafell, B. Bonne-Tamir et al. // Hum. Hered. 1999. — V. 49. — P. 15−20.
- Mateu, E. Worldwide genetic analysis of the CFTR region / E. Mateu, F. Calafell, O. Lao et al. // Am. J. Hum. Genet. 2001. — V. 68. — P. 103−117.
- Mateu, E. Can a place of origin of the main cystic fibrosis mutations be identified? / E. Mateu, F. Calafell, M.D. Ramos et al. // Am. J. Hum. Genet. -2002.-V. 70.-P. 257−264.
- Matthay, M.A. Alveolar epithelium. Role in lung fluid balance and acute lung injury / M.A. Matthay, L. Robriquet, X. Fang // Proc. Am. Thorac. Soc. 2005. -V.2.-P. 206−213.
- Matthews, R.P. Characterization of the cAMP response element of the cystic fibrosis transmembrane conductance regulator gene promoter / R.P. Matthews, G.S. McKnight// J. Biol .Chem. 1996. -V. 271, No. 50. — P. 31 869−31 877.
- McKay, K.O. The influence of newborn screening for cystic fibrosis on pulmonary outcomes in New South Wales / K.O. McKay, D.L. Waters, K.J. Gaskin // J. Pedatr. 2005. — V. 147 (3 Suppl.). — S. 47−50.
- McKone, E.F. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study / E.F. McKone, S.S. Emerson, K.L. Edwards, M.L. Aitken//Lancet.-2003.-V. 361 (9370).-P. 1671−1676.
- Mehta, G. Confidential anonymous audit shows that neonatal CF screening saves lives in severe genotype CF / G. Mehta, M. Green, A. Mehta // J. Cystic. Fibrosis. 2001. — Suppl. — WS2.
- Meindl, R.S. Hypothesis: a selective advantage for cystic fibrosis heterozygotes / R.S. Meindl // Am. J. Phys. Anthropol. 1987. — V. 74. — P. 39−45.
- Mei-Zahav, M. The prevalence and clinical characteristic of cystic fibrosis in South Asian Canadian immigrants / M. Mei-Zahav, P. Durie, J. Ziellenski et al. // Arch. Dis. Child. 2005. — V. 90, No. 7. — P. 675−679.
- Mekus, F. Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics / F. Mekus, M. Ballmann, I. Bronsveld et al. // Twin Res. 2000. — V. 3, No. 4. — P. 277−293.
- Mekus, F. Genes in the vicinity of CFTR modulate the cystic fibrosis phenotype in highly concordant or discordant F508del homozygous sib pairs / F. Mekus, U. Laabs, H. Veeze, B. Tummler // Hum. Genet. 2003. — V. 112, No. 1. — P. 1−11.
- Merelle, M.E. Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients / M.E. Merelle, J.P. Schouten, J. Gerritsen, J.E. Dankert-Roelse // Eur. Respir. J. 2001. — V. 18. — P. 306−315.
- Merelle, M.E. Early versus late diagnosis: psychological impact on parents of children with cystic fibrosis / M.E. Merelle, J. Huisman, A.A. van der Vecht et al.// Pediatrics. 2003. — V. 111. — P. 346−350.
- Mira, J.-P. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study / J.-P. Mira, A. Cariou, F. Grail et al. // J.A.M.A. 1999. — V. 282. — P. 561−568.
- Mishra, A. The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era / A. Mishra, R. Greaves, J. Massie // Clin. Biochem.Rev. 2005. -V. 26. — P. 135−153.
- Miyahara, K. Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene / K. Miyahara, T. Kawamoto, K. Sase et al. // Eur. J. Biochem. 1994. — V. 223, No. 3. — P. 719−26.
- Modiano, G. Cystic fibrosis and lactase persistence: a possible correlation / G. Modiano, B.M. Ciminelli, P. F. Pignatti // Eur. J. Hum. Genet. 2007. — V. 15 — P. 255−259.
- Moffatt, M.F. Tumour necrosis factor haplotypes and asthma / M.F. Moffatt, W.O. Cookson // Hum. Mol. Genet. 1997. — V. 6, No. 4. — P. 551−554.
- Moffett, S.P. Tumor necrosis factor-alpha polymorphism, born strength, and the risk of fracture in older women / S.P. Moffett, J.M. Zmuda, J.I. Oakley et al. // J. Clin. Endocrinol. Metab. 2005. — V. 90, No. 6. — P. 3491−3497.
- Mohammed, N.A. Expression of nitric oxide synthase isoforms in human liver cirrhosis / N.A. Mohammed, S. Abd El-Aleem, I. Appleton et al. // J. Pathol. -2003. V. 200, No. 5. — P. 647−655.
- Moller-Kristensen, M. Deficiency of mannan-binding lectin greatly increases susceptibility to postburn infection with Pseudomonas aeruginosa / M. Moller-Kristensen, W.K. Eddie Ip, L. Shi et al. // J. Immunol. 2006. — V. 176. — P. 1769−1775.
- Monti, L.D. Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome / L.D. Monti, C. Barlassina, L. Citterio et al. // Diabetes. 2003. — V. 52, No. 5.- P. 1270−1275.
- Morral, N. CA/GT microsatellite alleles within the cystic fibrosis transmembrane conductance regulator (CFTR) gene are not generated by unequal crossingover / N. Morral, V. Nunes, T. Casals, X. Estivill // Genomics. 1991. -V. 10.-P. 692−698.
- Morral, N. Dinucleotide (CA/GT) repeat polymorphism in intron 17B of the cystic fibrosis transmembrane conductance regulator (CFTR) gene / N. Morral, E. Girbau, J. Zielenski et al. // Hum. Genet. 1992. — V. 88. — P. 356.
- Morral, N. Microsatellite haplotypes for cystic fibrosis: mutation frameworks and evolutionary tracers / N. Morral, V. Nunes, T. Casals et al. // Hum. Mol. Genet. 1993. — V. 2. -N. 7. -P.l 015−1022.
- Morral, N. The origin of the major cystic fibrosis mutation (AF508) in European populations / N. Morral, J. Bertranpetit, X. Estivill et al. // Nat. Genet. -1994a.-V. 7.-P. 169−175.
- Morral, N. Independent origins of cystic fibrosis mutations R334W, R347P, R1162X, and 3849+lOkbC—>T provide evidence of mutation recurrencein the CFTR gene / N. Morral, R. Llevadot, T. Casals et al. // Am. J. Hum. Genet. -1994b.-V. 55.-P. 890−898.
- Moulin, D.S. A CA repeat in the first intron of the CFTR gene / D.S. Moulin, A.N. Smith, A. Harris // Hum. Hered. 1997. — V. 47. — P. 295−297.
- Mukhopadhyay, S. Role of TNFalpha in pulmonary pathophysiology / S. Mukhopadhyay, J.R. Hoidal, Т.К. Mukherjee // Respir. Res. 2006. — V. 11., No. 7.-P. 125.
- Murray, J. Screening for cystic fibrosis / J. Murray, H. Cuckle, G. Taylor et al. // Health Technol. Assess. 1999. — V. 3. — P. 1−104.
- Nataraj, A.J. Single-strand conformation polymorphism and heteroduplex analysis for gel-based mutation detection / A.J. Nataraj, I. Olivos-Glander, N. Kusukawa et al. // Electrophoresis. 1999. — V. 20 — P. 1177−1185.
- Nedwin, G.E. Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization / G.E. Nedwin, S.L. Naylor, A.Y. Sakaguchi et al. // Nuc. Ac. Res. 1985. — V. 13. — P. 6361−6373.
- Neuman, M. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis / M. Neuman, P.
- Angulo, I. Malkiewicz et al. // J. Gastroenterol. Hepatol. 2002. — V. 17, No. 2. -P. 196−202.
- Nicolae, D. Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21 / D. Nicolae, N.J. Cox, L.A. Lester et al. // Am. J. Hum. Genet. 2005. — V. 76, No. 2. — P. 349−357.
- Nissim-Rafinia, M. Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations / M. Nissim-Rafinia, O. Chiba-Falek, G. Sharon et al. // Hum. Mol. Genet. 2000. — V. 9. — P. 1771−1778.
- Nissim-Rafinia, M. Splicing regulation as a potential genetic modifier / M. Nissim-Rafinia, B. Kerem // Trends in Genet. 2002. — V. 18. — No. 3 — P. 123 127.
- Niwa, Y. Lymph otoxin-a polymorphisms and the risk of endometrial cancer in Japanese subjects / Y. Niwa, H. Ito, K. Matsuo et al. // Gynecol.Oncol. 2006. -V. 104, No. 3.-P. 586−590.
- Ng, I.S.I. Methods for analysis of multiple cystic fibrosis mutations / I.S.I. Ng, R. Pace, M.V. Richard et al. // Hum. Genet. 1991. — V. 87, No. 5. — P. 613−617.
- Norek, A. Genetic markers in the pathogenesis of osteopenia and osteoporosis in cystic fibrosis. / A. Norek, B. Romanowska-Pietrasiak, J. Bal // Med. Wieku Rozwoj. 2006. — V. 10, (1 Pt 2). — P. 275−287.
- Northrup, H. Additional polymorphism for D7S8 linked to cystic fibrosis including detection by DNA amplification / H. Northrup, C. Rosenbloom, W.E. O’Brien, A.Z. Beaudet // Nuc. Ac. Res. 1989. — V. 17. — No. 4. — P. 1717.
- Nuthall, H.N. A. Analysis of a DNase I hypersensitive site located -20.9 kb upstream of the CFTR gene / H.N. Nuthall, G. Vassaux, C. Huxley, A. Harris // Eur. J. Biochem.-1999a.-V. 266, No. 2. P. 431−43.
- Nuthall, H.N. Analysis of DNase-I-hypersensitive sites at the 3' end of the cystic fibrosis transmembrane conductance regulator gene (CFTR) / H.N. Nuthall, D. S. Moulin, C. Huxley, A. Harris // Biochem. J. 1999b. — V. 341, (Pt3). — P. 601−11.
- Ogino, S. Bayesian analysis and risk assessment in genetic counseling and testing / S. Ogino, R.B. Wilson // J. Mol. Diag. 2004a. — V. 6, No. 1. — P. 1−9.
- Ogino, S. Bayesian analysis for cystic fibrosis risks in prenatal and carrier screening / S. Ogino, R.B. Wilson, B. Gold et al. // Genet. Med. 2004b. — V. 6, No. 5.-P. 439−449.
- Ogino, S. Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests / S. Ogino, P. Flodman, R.B. Wilson et al. // Genet. Med. 2005. — V. 7, No. 5. — P. 317−327.
- Olds, L.C. Lactase persistence DNA variant enhances lactase promoter activity in vitro: functional role as a cis regulatory element / L.C. Olds, E. Sibley // Hum. Mol. Genet. -2003. -V. 12. P. 2333−2340.
- Ozaki, K. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction / K. Ozaki, Y. Ohnishi, A. Iida et al.// Nature Genet. 2002. — V. 32. — P. 650−654.
- Padoan, R. Genetic and clinical features of false-negative infants in a neonatal screening programme for cystic fibrosis / R. Padoan, S. Genoni, E. Moretti et al. // Acta Paediatr. 2002. — V.91, No. 1. — P. 82−87.
- Parad, R.B. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm / R.B. Parad, A.M. Comeau // J. Pediatr. 2005. — V. 147, (3 Suppl.). — S. 78−82.
- Park, K.S. Ncol restriction fragment length polymorphism at -308 of the tumor necrosis factor alpha (TNFA) promoter region in Korean / K.S.Park, M.Y. Kim, J.W. Мок // Jpn. J. Hum. Genet. 1997. — V. 42, No. 1. — P. 241−247.
- Pastinen, T. Influence of human genome polymorphism on gene expression / T. Pastinen, B. Ge, T.J. Hudson // Hum. Mol. Genet. 2006. — V. 15, Spec. No 1. -R 9−16.
- Patuzzo, C. Tumor Necrosis Factor Gene Complex in COPD and Disseminated. Bronchiectasis / C. Patuzzo, L.S. Gile, M. Zorzetto et al. // Chest. 2000. — V. 5, No. 117.-P. 1353−1358.
- Peterlin, B. A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes / B. Peterlin, M. Globocnik Petrovic, J. Makuc et al. // J. Hum. Genet. 2003 — V. 48, No. 12. -P. 646−649.
- Pier, G.B. Salmonella typhi uses CFTR to enter intestinal epithelial cells / G.B. Pier, M. Grout, T. Zaidi et al. // Nature. 1998. — V. 393. — P. 79−82.
- Pirzada, O. Modifier genes and cystic fibrosis liver disease / O. Pirzada, C. Taylor // Hepatology. 2003. — V. 37, No.3. — P. 714.
- Prokunina, L. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans / L. Prokunina, C. Castillejo-Lopez, F. Oberg et al. // Nat. Genet. 2002. — V. 32, No. 4. — P. 666 669.
- Quinton, P.M. Human Genetics. What is good about cystic fibrosis? / P.M. Quinton // Curr. Biol. 1994. — V. 4. — P. 742−743.
- Ratjen, F. Cystic Fibrosis / F. Ratjen, G. Doring // Lancet. 2003. — V. 361. -P. 681−689.
- Rave-Harel, N. The molecular basis of splicing mutations in cystic fibrosis / N. Rave-Harel, E. Kerem, M. Nissim-Rafinia et al. // Am. J. Hum. Genet. 1997. -V. 60.-P. 87−94.
- Reiss, J. Discrimination between recurrent mutation and identity by descent: application to point mutations in exon 11 of the cystic fibrosis (CFTR) gene / J. Reiss, D. N. Cooper, J. Bal et al. // Hum. Genet. 1990. — V. 47, No. 4. — P. 457 461.
- Riordan, J.R. Identification of the cystic fibrosis gene: Cloning and the characterization of complementary DNA / J.R. Riordan, J.M. Rommens, B. S. Kerem et al. // Science. 1989. — V. 245. — P. 1066−1073.
- Rock, M.J. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing / M.J. Rock, G. Hoffman, R.H. Laessig et al. // J. Pediatr. 2005. — V. 147. (3 Suppl.). — S. 73−77.
- Rohlfs, E.M. Is the hemochromatosis gene a modifier locus for cystic fibrosis? / E.M. Rohlfs, N.J. Shaheen, L.M. Silverman // Genet. Test. 1998. — V. 2, No. 1. -P. 85−88.
- Roque, M. Population screening of F508del (DeltaF508), the most frequent mutation in the CFTR gene associated with cystic fibrosis in Argentina / M. Roque, C.P. Godoy, M. Castellanos et al. // Hum. Mutat. 2001. — V. 18. — P. 167.
- Rosenbloom, C.L. DNA amplification for detection of the XV-2c polymorphism to cystic fibrosis / C.L. Rosenbloom, B.S. Kerem, J.M. Rommens et al. //Nuc. Ac. Res. 1989.-V. 17.-No. 17.-P. 7117.
- Rosenfeld, M. Overview of published evidence on outcomes with early diagnosis from large US observational studies / M. Rosenfeld // J. Pediatr. 2005. -V. 147, (3 Suppl.). — S. 11−14.
- Rosenstein, B.J. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel / B.J.Rosenstein, G.R. Cutting // J. Pediatr. -1998.-V. 132.-P. 589−595.
- Rosenstein, B.J. Cystic fibrosis / B.J. Rosenstein, P.L. Zeitlin // Lancet. 1998. -V. 351.-P. 277−82.
- Rowntree, R.K. The phenotypic consequences of CFTR mutations / R.K. Rowntree, A. Harris // Ann. Hum. Genet. 2003. — V. 67. — P. 471−485.
- Russo, M.P. Analysis of linkage disequilibrium between different cystic fibrosis mutations and three intragenic microsatellites in the Italian population / M.P. Russo, G. Romeo, M. Devoto et al. // Flum. Mutat. 1995. — V. 5. — P. 23−27.
- Ryley, H.C. Assay of serum immunoreactive trypsin in dried blood spots and the early detection of cystic fibrosis / H.C. Ryley, P.G. Robinson // J. Clin. Pathol. 1981. — V. 34, No. 8. — P. 906−910.
- Sabeti, P.C. Detecting recent positive selection in the human genome from haplotype structure / P.C. Sabeti, D.E. Reich, J.M. Higgins et al. // Nature. 2002. -V.419.-P. 832−837.
- Salvatore, F. Genotype-phenotype correlation in cystic fibrosis: The role of modifier genes / F. Salvatore, O. Scudiero, G. Castaldo // Am. J. Med. Genet.2002.-V. 111.-P. 88−95.
- Sampietro, M. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda / M. Sampietro, A. Piperno, L. Lupica et al. // Hepatology. 1998. — V. 27. — No. 1. — P. 181−184.
- Sanchez, M. Population screening for hemochromatosis: a study in 5370 Spanish blood donors / M. Sanchez, M. Villa, M. Ingelmo et al. // J. Hepatol.2003.-V. 38, (6)-P. 745−750.
- Sant’Agnese di, P.A. Abnormal electrolyted composition of sweat in cystic fibrosis of the pancreas / P.A. di Sant’Agnese, R. Darling, G. Perera, E. Shea // Pediatrics.- 1953.-N. 12.-P. 549−551.
- Schmidtke, J. Linkage relationships and allelic associations of the cystic fibrosis locus and four marker loci / J. Schmidtke, M. Krawczak, M. Schwartz et al. // Hum. Genet. 1987. -V. 76. — No. 4. — P. 337−343.
- Schmitt-Grohe, S. TNF-alpha promoter polymorphism in relation to TNF-alpha production and clinical status in cystic fibrosis / S. Schmitt-Grohe, F. Stuber, M. Book et al. // Lung. 2006 — V. 184, No. 2. — P. 99−104.
- Schroeder, S.A. Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis / S.A. Schroeder, D.M. Gaugham, M. Swift // Nat. Med. 1995. — V. 1. — P. 703−705.
- Scotet, V. Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis / V. Scotet, M. de Braekeleer, M. Roussey et al. // Lancet. 2000. — V. 356. — P. 789−94.
- Scotet, V. Prevalence of CFTR mutations in hypertyisimaemia detected through neonetal screening for cystic fibrosis / V. Scotet, M. de Braekeleer, M.P. Audrezet et al. // Clin. Genet. 2001. — V. 59, No. 1. — P. 42−47.
- Scotet, V. Prenatal detection of cystic fibrosis by ultrasonograthy: a retrospective study of more than 346 000 pregnancies / V. Scotet, M. de Braekeleer, M.P. Audrezet et al. // J. Med. Genet. 2002. — V. 39. — P. 443−448.
- Scotet, V. Impact of public health strategies on the birth prevalence of cystic fibrosis in Brittany, France / V. Scotet, M.P. Audrezet, M. Roussey et al. // Hum. Genet. 2003. — V. 113. — P. 280−285.
- Sekut, L. AntiTNF-alpha agents in the treatment of inflammation / L. Sekut, K. Connolly // Expert. Opin. Investig. Drugs. 1998. -V. 7, No. 11. — P. 1825−1839.
- Sereth, H. Extented haplotype analysis of cystic fibrosis mutations and its implications for the selective advantage hypothesis / H. Sereth, T. Shoshni, N. Bashan, B. S. Kerem // Hum. Genet. 1993. — V. 92, No. 3. — P. 289−295.
- Sermet-Gaudelus, I. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study / I. Sermet-Gaudelus, M. Renouil, A. Fajac et al. // B.M.C. Med. 2007. — V.5. P. 5.
- Shin, H.D. Association of tumor necrosis factor polymorphisms with asthma and serum total IgE / H.D. Shin, B.L. Park, L.H. Kim et al. // Hum.Molec.Genet. -2004.-V.13: 397−403.
- Simon-Bouy, B. Hyperechonenic fetal bowel: a large French collaborative study of 682 cases / B. Simon-Bouy, V. Satre, C. Ferec et al. // Am. J. Med. Genet. -2003. V. 121, No. 3. — P. 209−213.
- Sims, E.J. Newborn screening for cystic fibrosis is associated with reduced treatment intensity / E.J. Sims, J. McCormick, G. Mehta et al. // J. Pediatr. 2005. -V. 147, No. 3.-P. 306−11.
- Slatkin, M. The use of intraallelic variability for testing neutrality and estimating population growth rate / M. Slatkin, G. Bertorello // Genetics. 2001. -V. 158.-P. 865−874.
- Sontag, M.K. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes / M.K. Sontag, K.B. Hammond, J. Zeilenski et al. // J. Pediatr. 2005. -V. 147, 3 Suppl. — S. 83−88.
- Southern, K.W. Neonatal cystic fibrosis screening worldwide / K.W. Southern, J. M. Littlewood // Paediatric Respiratory Reviews. 2003. — V. 4, No. 4. — P. 299−305.
- Southern, K.W. A survey of newborn screening of cystic fibrosis in Europe / K.W. Southern, A. Munck, R. Pollitt et al, on behalf of the ECFS CF Neonatal Screening Working Group // J. Cyst. Fibros. 2007. — V. 6, No. 1. — P. 57−65.
- Strange, R.C. The human glutathione S-transferases: studies on the tissue distribution and genetic variation of the GST1, GST2 and GST3 isozymes / R.C. Strange, C.G. Faulder, В .A. Davis et al. // Ann. Hum. Genet. 1984. — V. 48. — P. 11−20.
- Streit, C. CFTR gene: molecular analysis in patients from South Brazil / C. Streit, A.C. Burlamaque-Neto, F. de Abreu e Silva et al. // Mol. Genet. Metab. -2003. V. 78, No. 4. — P. 259−264.
- Suwanjutha, S. Case report of a Thai male cystic fibrosis patient with the 1898+1G—>T splicing mutation in the CFTR gene: A review of East Asian cases / S. Suwanjutha, N.N. Huang, D. Wattanasirichaigoon et al. // Hum. Genet. 1998. -V. 12. — P. 361.
- Tanus-Santos, J.E. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants / J.E. Tanus-Santos, M. Desai, D.A. Flockhart // Pharmacogenetics. -2001. V. 11, No. 8. — P. 719−25.
- The molecular genetic epidemiology of cystic fibrosis. Report of a Joint Meeting of WHOACF (M)A/ECFTN / World Health Organization (WHO) // Stockholm, Sweden, 3 June 2000. Human Genetics Programme. — Geneva, 2001. — 7 p.
- The molecular genetic epidemiology of cystic fibrosis. Report of a Joint Meeting of WHO/ECFTN/ICF (M)/ECFS / World Health Organization (WHO) // Genoa, Italy, 19 June 2002. Human Genetics Programme. — 2004. — 24 p.
- Thiagarajah, J.R. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor / J. R. Thiagarajah, T. Broadbent, E. Hsieh, A. S. Verkman // Gastroenterology. 2004. — V. 126, No. 2. — P. 511−519.
- Thio, C.L. Mannose binding lectin genotypes influence recovery from hepatitis В virus infection / C.L. Thio, T. Mosbruger, J. Astemborski et al. // J. Virol. -2005.-V. 79, No. l 4.-P. 9192−9196.
- Tolstova, V.D. First results of Newborn screening program for CF in Russia / V.D. Tolstova, N.Y. Kashirskaya, N.I. Kapranov, A.A. Khodunova, E.V. Denisenkova, E.V. Smazhil // J. Cyst. Fibr. 2008. — |ГТз.
- Tomatsu, S. Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis / S. Tomatsu, K.O. Orii, R.E. Fleming et al. // Proc. Natl. Acad. Sci. USA.- 2003. V. 100, No. 26. — P. 15 788−93.
- Tsui, L.C. The spectrum of cystic fibrosis mutation / L.C. Tsui // Trends Genet. 1992. — V. 8.-P. 392−8.
- Tsukada, T. Evidence of association of the eNOS gene polymorphism with plasma NO metabolite levels in humans / T. Tsukada, K. Yokoyama, T. Arai et al. //Biochem. Biophys. Res. Commun. 1998. — V. 245, No. 1. — P. 190−193.
- Turner, M.W. Mannose-binding lectin (MBL) in health and disease / M.W. Turner//Immunobiology. 1998. -V. 199. — P. 327−339.
- Vankeerberghen, A. Charaterization of mutations located in exon 18 of the CFTR gene / A. Vankeerberghen, L. Wei, H. Teng et al. // FEBS Lett. 1998b. -V. 437.-P. 1−4.
- Vanscoy, L.L. Heritability of lung disease severity in cystic flbfosis / L.L. Vanscoy, S.M. Blackman, J.M. Collaco et al. // Am. J. Respir. Crit. Care Med. -2007. doi:10.1164/rccm.200 608-l 1640C.
- Verdu, P. Evolutionary insights into the high worldwide prevalence of MBL2 deficiency alleles / P. Verdu, L. B. Barreiro, E. Patin et al. // Hum. Mol. Genet. -2006.-V. 15, No, 17.-P. 2650−2658.
- Verlingue, C. Complete screening of the coding sequence of the CFTR gene in a sample of CF patients from Russia: Identification of three novel mutations / C. Verlingue, N.I. Kapranov, B. Mercier et al. // Hum. Genet. 1995. — V. 5. — P. 205−209.
- Vosse van de, E. Susceptibility to typhoid fever is associated with a polymorphism in the cystic fibrosis trans membrane conductance regulator (CFTR) / E. van de Vosse, S. Ali, A. W. Visser et al. // Hum. Genet. 2005. — V. 118, No. 1.- P. 138−140.
- Wang, S.S. The impact of early cystic fibrosis diagnosis on pulmonary function in children / S.S. Wang, L.A. O’Leary, S.C. FitzSimmons, M.J. Khoury // J. Pediatr. 2002. — V. 141.-P. 804−810.
- Warwick, W.J. Letter to the Editor / W.J. Warwick, J. Braverman // Chronic Respiratory Diseases.-2007. V. 4.-P. 51−51.
- Wei, L. Suppressive interactions between mutations located in the two nucleotide binding domains of CFTR / L. Wei, A. Vankeerberghen, M. Jaspers et al. // FEBS. 2000. — V. 473. — P. 149−153.
- Wei, S. Cystic fibrosis testing among Arab-Americans / S. Wei, G. L. Feldman, K. G. Monaghan // Genet. Med. 2006. — V. 8, No. 4. — P. 255−258.
- Weijers-Poppelaars, F.A. Preconception cystic fibrosis screening: costs and consequences / F.A. Weijers-Poppelaars, M.F. Wildhagen, L. Henneman et al. // Genet. Test. 2005. — V.9, No. 2. — P. 158−166.
- Welsh, M.J. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis / M.J. Welsh, A.E. Smith // Cell. 1993. — V.73. — P.1252−1254.
- Westwood, T. Diagnosing cystic fibrosis in South Africa / T. Westwood, B. Henderson, M. Ramsay // S. Afr. Med. J. 2006b. — V. 96, No. 4. — P. 304−306.
- Wiertsema, S.P. Functional polymorphisms in the mamman-binding lectin 2 gene: effect on MBL levels and otitis media / S.P. Wiertsema, B.L. Herpers, R. H. Veenhoven et al. // J. Allergy Clin. Immunol. 2006. — V. 117, No. 6. — P. 13 441 350.
- Wilcken, B. Evaluating outcomes of newborn screening programs / B. Wilcken // Southeast Asian J. Trop. Med. Public. Health. 2003. — V. 34. — Suppl. 3. — P. 13−18.
- Wilfond, B. S. Policy issues for expanding newborn screening programs: The cystic fibrosis newborn screening on cystic fibrosis testing in Victoria, Australia / B.S. Wilfond, S.E. Gollust // J. Pediatr. 2005. — V. 146. — P. 668−674.
- Williams, С. Same-day, first-trimester antenatal diagnosis for cystic fibrosis by gene amplification / C. Williams, B. Williamson, C. Coutelle // Lancet. 1988. -July 9- 2(8602) -P.102−103.
- Wilson, A.G. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation / A.G. Wilson, J.A. Symons, T.L. McDowell et al. // Proc. Natl. Acad. Sci. USA.- 1997. V.l. — No. 94 (7). — P. 3195−3199.
- Witt, H. Chronic pancreatitis and cystic fibrosis / H. Witt // Gut. 2003. — Suppl. 2. — P. 1131−1141.
- Witte, J.S. Relation between tumour necrosis factor polymorphism TNF-alpha-308 and risk of asthma / J.S. Witte, L.J. Palmer, R.D. O’Connor et al. // Europ. J. Hum. Genet. 2002. — V. 10. — P. 82−85.
- Wiuf, C. Do delta F508 heterozygotes have a selective advantage? / C. Wiuf // Genet. Res. 2001. — V. 78, No. 1. — P. 41−47.
- Wright S.W. Genetic studies on cystic fibrosis in Hawaii / S.W. Wright, N.E. Morton // Am. J. Hum. Genet. 1968. — V. 20. — P. 157−169.
- Yanamandra, K. Novel allele of the endothelial nitric oxide synthase gene polymorphism in Caucasian asthmatics / K. Yanamandra, P.B. Boggs, T.F. Thurmon et al. // Biochemical and Biophysical Research Communications. 2005. — V. 335. — P. 545 -549.
- Yarden, J. Polymorphism in the mannose binding lectin gene affects the cystic fibrosis pulmonary phenotype / J. Yarden, D. Radojkovic, K. de Boeck et al. // J. Med. Genet. 2004. — V. 41. — P. 629−633.
- Yarden, J. Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype / J. Yarden, D. Radojkovic, K. de Boeck et al. // Thorax. -2005. V. 60, No. 4. — P. 320−325.
- Yoshimura, K. The cystic fibrosis gene has a «housekeeping"-type promoter and is expressed at low levels in cells of epithelial origin / K. Yoshimura, H. Nakamura, B.C. Trapnell et al. // J. Biol. Chem. 1991. — V. 266, No. 14. — P. 9140−9144.
- Zhana, X. Expression of endothelial nitric oxide synthase in ciliated epithelia of rats / X. Zhana, D. Lia, R. A. Johnsa // J. Histochem. Cytochem. 2003. — V. 51. -P. 81−87.
- Zhang, D.L. Association of two polymorphisms of tumor necrosis factor gene with biliary pancreatitis / D.L. Zhang, J.S. Li, Z.W. Jiang et al. // World J. Gastroenterol. 2003. — V. 4. — P. 824−828.
- Zhang, Z. Comparison of the use of body mass index percentiles and percentage of ideal body weight to screen for malnutrition in children with cystic fibrosis / Z. Zhang, H. Lay // Am. J. Clin. Nutr. 2004. — V. 80. — P. 982−91.
- Zhao, Q. Association study of the endothelial nitric oxide synthase gene polymorphisms with essential hypertension in northern Han Chinese / Q. Zhao, S.Y. Su, S.F. Chen et al. // Chin. Med. J. (Engl). 2006. — V. 119, No. 13. — P. 1065−1071.
- Zielenski, J. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator gene / J. Zielenski, R. Roozmahel, D. Bozon et al. // Genomics. 1991b.-No. 10. — P. 214−228.
- Zielenski, J. Cystic fibrosis: genotypic and phenotypic variations / J. Zielenski, L.C. Tsui // Annu. Rev. Genet. 1995. — V. 29. — P. 777−807.
- Zielenski, J. Genotype and phenotype in cystic fibrosis / J. Zielenski // Respiration. 2000. — V. 67, No. 2. — P. 117−133.